Bringing meaningful therapies from one to many: small-molecule precision medicines for rare genetic disease.
概要
Setara Biosciences is a San Diego-based biotech spun out of Actio Biosciences following Actio's acquisition by Jazz Pharmaceuticals. It develops small-molecule precision medicines led by STAR-0871, a TRPV4 inhibitor for Charcot-Marie-Tooth disease type 2C and overactive bladder.